[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352120-105":59,"doc-detail-352120-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","single-fraction-or-multi-fraction-stereotactic-ablative-body-radiotherapy-followed-by-atezolizumab-in-advanced-triple-negative-breast-cancer-a-randomized-phase-ii-trial","Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer - a randomized phase II trial","","Phase II multi-center AZTEC trial evaluated single-fraction (20 Gy) versus multi-fraction (24 Gy in three fractions) stereotactic ablative body radiotherapy (SABR) followed by anti–PD-L1 atezolizumab in 54 women with advanced triple-negative breast cancer. Progression-free survival was similar between arms, with median PFS 2.5 months (SF) and 3.1 months (MF), and the prespecified null hypothesis not rejected. Clinical benefit occurred in 20% (SF) and 25% (MF) with comparable safety. Exploratory peripheral blood analyses showed higher CD8 TPEX cells correlated with longer response duration. Combining SABR with atezolizumab was safe, with further study needed for oligometastatic TNBC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/single-fraction-or-multi-fraction-stereotactic-ablative-body-radiotherapy-followed-by-atezolizumab-in-advanced-triple-negative-breast-cancer-a-randomized-phase-ii-trial/352120/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/single-fraction-or-multi-fraction-stereotactic-ablative-body-radiotherapy-followed-by-atezolizumab-in-advanced-triple-negative-breast-cancer-a-randomized-phase-ii-trial/352120.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the AZTEC phase II randomized trial?","Question",{"text":112,"@type":113},"To assess the efficacy and safety of SABR delivered as single-fraction or multi-fraction regimens, followed by atezolizumab, in women with advanced triple-negative breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did progression-free survival compare between the single-fraction and multi-fraction arms?",{"text":117,"@type":113},"Median progression-free survival was similar: 2.5 months for the single-fraction arm versus 3.1 months for the multi-fraction arm, and the prespecified null hypothesis was not rejected in either arm.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors were explored to understand differences in treatment response?",{"text":121,"@type":113},"An exploratory analysis of peripheral blood found higher CD8 TPEX cells before and during treatment, which correlated with improved response duration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352120,1791144534,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-026-75660-y](https://doi.org/10.1038/s41467-026-75660-y)  \nSingle-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial  \nReceived: 20 July 2024  \n\n| Accepted: 8 July 2026 |\n| --- |\n| |\n| Check for updates |\n\nSteven David 1,2,12,13 , Peter Savas 2,3,12, Shankar Siva 1,2,  \nMathias Bressel 2,4, Michelle White5,6, Bronte Nikolic3, Michael W. Neeson3, Shane White7, Gavin Marx 8,9, Robyn Cheuk10, Michelle Grogan11, Maria Farrell4, Jessica Foudoulis4, Paul J. Neeson 3 & Sherene Loi 2,3,13   \nPre-clinical evidence suggests that stereotactic ablative body radiotherapy (SABR) can enhance systemic anti-tumor responses when combined with immune checkpoint inhibition, although optimal fractionation remains uncertain. Here we conducted a phase II multi-center randomized trial (AZTEC trial; ClinicalTrials.gov identiﬁer NCT03464942) to investigate the efﬁcacy and safety of single-fraction (SF: 20 Gy; n = 27) or multi-fraction(MF:24 Gy in three fractions; n = 27) SABR followed by anti-PD-L1 atezolizumab in 54 women with advanced triple-negative breast cancer (TNBC) as ﬁrst or second-line treatment. The primary endpoint was progression free survival (PFS). Secondary endpoints included best overall response rate, clinical beneﬁt rate, overall survival and safety. We observed that both treatment arms had similar efﬁcacy:  \nmedian PFS was 2.5 months (90% CI: 1.7-4.5) for SF and 3.1 months (90% CI: 1.8- 3.9) for MF. The null hypothesis (PFS of 2 months) was not rejected in either arm. Clinical beneﬁt (RECIST complete response/partial response or stable disease for ≥24 weeks) was achieved in 5 (20%) SF and 6 (25%) MF patients, all witholigometastatic disease, independent ofPD-L1expression. Adverse events were similar between arms. Prespeciﬁed exploratory analysis of peripheral blood found higher CD8 TPEX cells before and during treatment correlated with improved response duration. Combining SABR with atezolizumab is safe, however further testing is required to determine efﬁcacy for advanced TNBC patients with oligometastatic disease.  \nTherapeutic options for advanced triple-negative breast cancer (TNBC) are currently limited, contributing to its poor prognosis and often associated with signiﬁcant toxicity1–4. Immune checkpoint inhibitors (ICIs) are being investigated as a potential treatment avenue in advanced TNBC due to the cancer’s high mutational burden and  \nincreased expression of programmed death-ligand 1 (PD-L1)5,6. However, ICIs as monotherapy have yielded disappointing tumor response rates7–10 attributed to TNBC’s high levels of immunosuppressive molecules and pathways, including regulatory T cell inﬁltration, alongside tumor heterogeneity11–14.  \nA full list of afﬁliations appears at the end of the paper. e-mail: [steven.david@petermac.org](steven.david@petermac.org); [sherene.loi@petermac.org](sherene.loi@petermac.org)  \nConsequently, combination approaches targeting the immunosuppressive microenvironment and enhancing the anti-tumor immune response are being explored15,16. Combining chemotherapy with ICIs has yielded positive oncological outcomesin recent randomized phase III trials17,18, leading to their approval for metastatic and neoadjuvant TNBC in combination with chemotherapy. Another strategy involves combining ICIs with radiotherapy. In addition to direct tumoricidal effects, radiotherapy doses in routine use may steer the immune microenvironment towards both pro-inﬂammatory and immunosuppressive states. A key pro-inﬂammatory mechanism is the induction of immunogenic cell death (ICD) by radiation, leading to the release of immune-stimulating tumor antigens that potentially transform tumors into in situ vaccines19–22. Both pre-clinical and clinical evidence support the notion that radiotherapy directed at metastatic sites can initiate a systemic immune response, resulting in tumor","cbCair4bdjHFEsF4","https://ap.wps.com/l/cbCair4bdjHFEsF4","pdf",834410,12,"English","# AZTEC trial design\n## Primary and secondary endpoints\n## Efficacy and safety results\n## Exploratory biomarker findings\n# Rationale and background for SABR plus immune checkpoint inhibition","[{\"question\":\"What was the main goal of the AZTEC phase II randomized trial?\",\"answer\":\"To assess the efficacy and safety of SABR delivered as single-fraction or multi-fraction regimens, followed by atezolizumab, in women with advanced triple-negative breast cancer.\"},{\"question\":\"How did progression-free survival compare between the single-fraction and multi-fraction arms?\",\"answer\":\"Median progression-free survival was similar: 2.5 months for the single-fraction arm versus 3.1 months for the multi-fraction arm, and the prespecified null hypothesis was not rejected in either arm.\"},{\"question\":\"What factors were explored to understand differences in treatment response?\",\"answer\":\"An exploratory analysis of peripheral blood found higher CD8 TPEX cells before and during treatment, which correlated with improved response duration.\"}]","Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer - a randomized phase II trial | PDF",1790097784,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c09ceeec0581bbcd32cba5f7d3c084b.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf9690054e1526a2b426232c8ba80e60.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b91157a164cb3f2970adc8b6453fef67.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3794c049dd80801da7b92eae0fcf784.webp",980,1301]